A trial of RVT-103 for the treatment Alzheimer's disease and Lewy-body dementia.

Trial Profile

A trial of RVT-103 for the treatment Alzheimer's disease and Lewy-body dementia.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Donepezil/glycopyrrolate (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 13 Jun 2017 Results published in an Axovant Sciences Media Release
    • 13 Jun 2017 According to an Axovant Sciences media release, the company is planning a RVT-104 proof of concept study (see profile 285954) based on data from this trial. This trial measured subject nausea in 48 healthy, elderly subjects.
    • 09 Jan 2017 According to an Axovant Sciences media release, the first portion of the study has been competed and second portion of the study has begun. Results from the study are expected in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top